3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia
31
Leukemia, Promyelocytic, Acute
26
Multiple Myeloma
17
Leukemia, Myeloid, Acute
16
Neoplasms, Plasma Cell
12
Myelodysplastic Syndromes
12
Leukemia, Myelomonocytic, Chronic
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Anemia, Refractory, with Excess of Blasts
7
Lymphoma
6
Leukemia, Monocytic, Acute
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Blast Crisis
6
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Leukemia, Myelomonocytic, Acute
5
Leukemia, Megakaryoblastic, Acute
5
Leukemia, Erythroblastic, Acute
5
Burkitt Lymphoma
5
Recurrence
4
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Central Nervous System Neoplasms
4
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
Arsenic Trioxide
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled